Zhaojin F. Yu

77 Puhe Road
Shenyang, 110122, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 55 publications

Dysregulated immune microenvironment in metastatic colorectal cancer.

Dysregulated immune microenvironment in metastatic colorectal cancer.

Journal: Medical oncology (Northwood, London, England)

Published: June 09, 2025

Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals.

Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals.

Journal: Journal of hematology & oncology

Published: December 26, 2024

When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside?

When will the immune-stimulating antibody conjugates (ISACs) be transferred from bench to bedside?

Journal: Pharmacological research

Published: January 21, 2024

Current status and trends in small nucleic acid drug development: Leading the future.

Current status and trends in small nucleic acid drug development: Leading the future.

Journal: Acta pharmaceutica Sinica. B

Published: December 21, 2023

Analysis on the status quo of the awareness rate of core knowledge of cancer prevention and treatment and its influencing factors among residents in Liaoning Province in 2021

Analysis on the status quo of the awareness rate of core knowledge of cancer prevention and treatment and its influencing factors among residents in Liaoning Province in 2021

Journal: Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]

Published: January 19, 2023

Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application.

Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application.

Journal: Frontiers in oncology

Published: November 25, 2022

Retraction Notice to: miR-181a Induces Macrophage Polarized to M2 Phenotype and Promotes M2 Macrophage-mediated Tumor Cell Metastasis by Targeting KLF6 and C/EBPα.

Retraction Notice to: miR-181a Induces Macrophage Polarized to M2 Phenotype and Promotes M2 Macrophage-mediated Tumor Cell Metastasis by Targeting KLF6 and C/EBPα.

Journal: Molecular therapy. Nucleic acids

Published: June 27, 2022

Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?

Peptide-drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?

Journal: Acta pharmaceutica Sinica. B

Published: May 09, 2022

Advances of research of Fc-fusion protein that activate NK cells for tumor immunotherapy.

Advances of research of Fc-fusion protein that activate NK cells for tumor immunotherapy.

Journal: International immunopharmacology

Published: January 26, 2022

Corrigendum to 'Silencing KIF18B enhances radiosensitivity: Identification of a promising therapeutic target in sarcoma' [EBioMedicine 61 (2020) 103,056].

Corrigendum to 'Silencing KIF18B enhances radiosensitivity: Identification of a promising therapeutic target in sarcoma' [EBioMedicine 61 (2020) 103,056].

Journal: EBioMedicine

Published: November 25, 2021

Erratum: MiR-487a Promotes TGF-β1-induced EMT, the Migration and Invasion of Breast Cancer Cells by Directly Targeting MAGI2.

Erratum: MiR-487a Promotes TGF-β1-induced EMT, the Migration and Invasion of Breast Cancer Cells by Directly Targeting MAGI2.

Journal: International journal of biological sciences

Published: October 21, 2021

Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine.

Correction to: HLA-A2.1-restricted ECM1-derived epitope LA through DC cross-activation priming CD8+ T and NK cells: a novel therapeutic tumour vaccine.

Journal: Journal of hematology & oncology

Published: September 30, 2021

Showing 1-12 of 55

Last Updated: 09/26/2026